78 Participants Needed

Antiplatelet Therapy Strategies for Coronary Artery Disease

(SWAP-8 Trial)

LO
AB
Overseen ByAndrea Burton, MPH, CCRP
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: University of Florida
Must be taking: Low-dose aspirin, Prasugrel, Ticagrelor
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it seems you need to be on a specific dual antiplatelet therapy (DAPT) with low-dose aspirin and either prasugrel or ticagrelor to participate. If you are on other medications, especially oral anticoagulants, you may not be eligible.

What data supports the effectiveness of the drugs Clopidogrel and Prasugrel for coronary artery disease?

Research shows that both Clopidogrel and Prasugrel are effective in preventing heart attacks and death in patients with acute coronary syndrome, a condition related to coronary artery disease. Prasugrel may work faster and more consistently than Clopidogrel, but it might also increase the risk of bleeding in some patients.12345

Is antiplatelet therapy with Clopidogrel and Prasugrel safe for humans?

Both Clopidogrel and Prasugrel are generally safe for humans, but they can increase the risk of bleeding. Prasugrel may have a higher risk of bleeding compared to Clopidogrel, although it is more effective in preventing heart-related events.678910

How does the drug combination of Clopidogrel and Prasugrel differ from other treatments for coronary artery disease?

The combination of Clopidogrel and Prasugrel is unique because Prasugrel offers a faster onset of action and more consistent platelet inhibition compared to Clopidogrel, making it particularly effective for patients with acute coronary syndrome and those undergoing coronary interventions. However, it also carries a higher risk of bleeding, especially in older patients or those with lower body weight.1112131415

What is the purpose of this trial?

Dual antiplatelet therapy (DAPT) with low-dose aspirin and a P2Y12 inhibitor is the current standard of care in patients with coronary artery disease experiencing an acute event or undergoing percutaneous coronary intervention. However, the ischemic benefits are counterbalanced by a significant increase in bleeding events. Over time, different DAPT de-escalation strategies have been developed to reduce the bleeding risk while maintaining the ischemic protection, but there is currently no head-to-head comparison between them. The purpose of this clinical trial is to conduct a head-to-head comparison on the pharmacodynamic efficacy of DAPT de-escalation by dose reduction to low-dose prasugrel (5 mg od) and DAPT de-escation by switching from standard-dose more potent P2Y12 receptor inhibitor to standard-dose clopidogrel (75 mg). To determine if the PD profiles of these two strategies are comparable, we aim to conduct a non-inferiority study.

Eligibility Criteria

This trial is for patients with coronary artery disease who've had an acute event or a procedure to open their arteries. They must be on dual antiplatelet therapy but can't join if they have conditions that the study excludes, which aren't specified here.

Inclusion Criteria

Provide written informed consent.
I had a heart procedure, take specific heart medications, and it's been over 30 or 90 days since.

Exclusion Criteria

Prior history of stent thrombosis
Prior cerebrovascular event
I had a heart procedure within the last 30 days.
See 7 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo DAPT de-escalation by either dose reduction or switching, following PCI

4 weeks
1 visit (in-person) for PCI, followed by regular monitoring

Follow-up

Participants are monitored for platelet reactivity and safety after treatment

4 weeks
1 visit (in-person) for VerifyNow testing

Treatment Details

Interventions

  • Clopidogrel
  • Prasugrel
Trial Overview The study tests two ways to reduce bleeding risk in heart patients while protecting against clots: one group will take a lower dose of Prasugrel (5 mg), and another will switch to standard-dose Clopidogrel (75 mg). It's a head-to-head test to see if both methods are equally effective.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: DAPT de-escalation by dose-reductionExperimental Treatment1 Intervention
Group II: DAPT de-escalation by switchActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Florida

Lead Sponsor

Trials
1,428
Recruited
987,000+

Findings from Research

Aspirin is the primary antiplatelet therapy for secondary prevention of coronary artery disease (CAD), often used in combination with clopidogrel for patients undergoing procedures like percutaneous coronary intervention.
In patients with acute coronary syndrome, newer agents like prasugrel and ticagrelor provide better outcomes by reducing ischemic events, but they also carry a higher risk of bleeding compared to clopidogrel, with prasugrel being particularly effective for those with ST elevation myocardial infarction.
Antiplatelet therapy for secondary prevention of coronary artery disease.Pilgrim, T., Windecker, S.[2022]

References

Oral antiplatelet therapy for the management of acute coronary syndromes: defining the role of prasugrel. [2015]
Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction. [2021]
Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel. [2019]
Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). [2020]
[Platelet inhibition with prasugrel]. [2018]
Efficacy and Safety of Low-Dose Prasugrel Versus Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis. [2022]
Prasugrel: a novel antiplatelet agent. [2019]
Safety and Efficacy of Switching From Clopidogrel to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: A Study-level Meta-analysis From 15 Studies. [2022]
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. [2022]
Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development. [2019]
11.United Statespubmed.ncbi.nlm.nih.gov
Clinical profile of prasugrel, a novel thienopyridine. [2015]
[Prasugrel]. [2015]
Antiplatelet therapy for secondary prevention of coronary artery disease. [2022]
Republished: Antiplatelet therapy for secondary prevention of coronary artery disease. [2015]
Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security